

5th July 2017

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

IQNOVATE LTD – Extension of proposed Convertible Note Issue

Further to the announcement of 7th March 2017, iQnovate Ltd (IQN:NSX) announces that the Directors have resolved to keep the proposed Convertible Note Issue open to 31 October 2017. The Directors may also consider accepting applications in aggregate in excess of \$5,000,000 from sophisticated investors.



Gerardo Incollingo

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Limited

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

IQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.